Patient with ovarian insufficiency: baby born after anticancer therapy and re-transplantation of cryopreserved ovarian tissue.
Baby born
Cancer
Cryopreservation
Cryoprotectants
Human ovarian tissue
Re-transplantation
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
29 Sep 2020
29 Sep 2020
Historique:
received:
05
08
2020
accepted:
08
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
9
7
2021
Statut:
epublish
Résumé
The second major cause of death is cancer. In fact, the effectiveness of anticancer treatments and positive long-term prognosis for young women has increased. However, the problem of post-cancer infertility plays a significant role, because chemotherapy can be gonadotoxic and lead to the functional death of ovaries. There is potential key solution to this problem: cryopreservation of ovarian tissue before cancer therapy with re-implantation after convalescence. Data regarding cryopreservation and re-transplantation of ovarian tissue from patients with ovarian insufficiency is limited. The aim of this treatment was the re-transplantation of cryopreserved ovarian tissue after anticancer therapy of patient with ovarian insufficiency (56 IU/l FSH, 8 ng/l β-estradiol, < 1.1 ng/ml anti-Mullerian hormone, 1 primary follicle per 10mm After the operation, four tissue fragments (10-16 × 8-13 × 1.0-1.2 mm) were cooled to 5 °C in the freezing medium (culture medium+ 6% ethylene glycol+ 6% dimethyl sulfoxide+ 0.15 M sucrose) for 24 h, frozen and thawed. Freezing was performed in four standard 5 ml cryo-vials with ice formation at - 9 °C, cooling from - 9 to - 34 °C at a rate of - 0.3 °C/min and plunging at - 34 °C into liquid nitrogen. After thawing in a 100 °C (boiling) water bath, the removal of cryoprotectants was performed in 0.5 M sucrose with 20 min. exposure in sucrose and 30 min. stepping rehydration. After thawing of one cryo-vial, part (5 mm Described protocol of conventional cryopreservation of ovarian tissue can be used for treatment of patients with ovarian insufficiency.
Sections du résumé
BACKGROUND
BACKGROUND
The second major cause of death is cancer. In fact, the effectiveness of anticancer treatments and positive long-term prognosis for young women has increased. However, the problem of post-cancer infertility plays a significant role, because chemotherapy can be gonadotoxic and lead to the functional death of ovaries. There is potential key solution to this problem: cryopreservation of ovarian tissue before cancer therapy with re-implantation after convalescence. Data regarding cryopreservation and re-transplantation of ovarian tissue from patients with ovarian insufficiency is limited. The aim of this treatment was the re-transplantation of cryopreserved ovarian tissue after anticancer therapy of patient with ovarian insufficiency (56 IU/l FSH, 8 ng/l β-estradiol, < 1.1 ng/ml anti-Mullerian hormone, 1 primary follicle per 10mm
CASE PRESENTATION
METHODS
After the operation, four tissue fragments (10-16 × 8-13 × 1.0-1.2 mm) were cooled to 5 °C in the freezing medium (culture medium+ 6% ethylene glycol+ 6% dimethyl sulfoxide+ 0.15 M sucrose) for 24 h, frozen and thawed. Freezing was performed in four standard 5 ml cryo-vials with ice formation at - 9 °C, cooling from - 9 to - 34 °C at a rate of - 0.3 °C/min and plunging at - 34 °C into liquid nitrogen. After thawing in a 100 °C (boiling) water bath, the removal of cryoprotectants was performed in 0.5 M sucrose with 20 min. exposure in sucrose and 30 min. stepping rehydration. After thawing of one cryo-vial, part (5 mm
CONCLUSIONS
CONCLUSIONS
Described protocol of conventional cryopreservation of ovarian tissue can be used for treatment of patients with ovarian insufficiency.
Identifiants
pubmed: 32993734
doi: 10.1186/s13048-020-00713-9
pii: 10.1186/s13048-020-00713-9
pmc: PMC7526427
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Références
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17474-9
pubmed: 24082083
Cryo Letters. 2009 Nov-Dec;30(6):449-54
pubmed: 20309501
Reprod Biol Endocrinol. 2016 Nov 10;14(1):79
pubmed: 27832793
Curr Opin Obstet Gynecol. 2016 Jun;28(3):217-22
pubmed: 27022685
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10280-4
pubmed: 20479243
Cryobiology. 2020 Apr;93:115-120
pubmed: 32014535
Cryobiology. 2007 Dec;55(3):261-8
pubmed: 17931616
N Engl J Med. 2017 Oct 26;377(17):1657-1665
pubmed: 29069558
J Ovarian Res. 2018 Aug 31;11(1):76
pubmed: 30170634
Cell Transplant. 2013;22(11):2053-61
pubmed: 23127502
PLoS One. 2015 Jun 17;10(6):e0129108
pubmed: 26083026
Reprod Biomed Online. 2020 Feb;40(2):245-253
pubmed: 31753712
Development. 2011 Jan;138(1):9-22
pubmed: 21138973
Cryo Letters. 2008 May-Jun;29(3):261-8
pubmed: 18754066
Lancet. 2010 Sep 11;376(9744):911-21
pubmed: 20708256
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Reprod Biomed Online. 2020 Feb;40(2):254-260
pubmed: 31956062
Reprod Sci. 2019 Feb;26(2):207-213
pubmed: 30541396
Hum Reprod. 2015 Mar;30(3):608-15
pubmed: 25567618
Eur J Cancer. 2009 Jun;45(9):1547-53
pubmed: 19264478
J Clin Endocrinol Metab. 2016 Nov;101(11):4405-4412
pubmed: 27571179
Reproduction. 2009 Aug;138(2):319-27
pubmed: 19439559
Hum Reprod. 2019 Oct 2;34(10):1924-1936
pubmed: 31593582
Science. 2008 Feb 1;319(5863):611-3
pubmed: 18239123
Fertil Steril. 2010 Feb;93(3):913-9
pubmed: 19108826
Reprod Biomed Online. 2004 May;8(5):553-7
pubmed: 15151719